Brief: Travere Therapeutics Q4 EPS USD 0.03
19/02/2026 21:01
Feb 19 (Reuters) - Travere Therapeutics Q4 operating expenses USD 162.117 million. Q4 product sales USD 126.608 million Q4 operating income USD -32.428 million Q4 net income USD 2.729 million
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule